


=&gt; d 127, ibib abs fhitr, 1

L27 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

Full  
TextCiting  
References

ACCESSION NUMBER: 1995:996505 HCAPLUS  
 DOCUMENT NUMBER: 124:146864  
 TITLE: Preparation of catechol-haptenated peptides for desensitizing against delayed-type hypersensitivity  
 INVENTOR(S): Hackett, Charles J.; Greenstein, Julia L.; Gefter, Malcolm L.; Wilson, Kurt Jeff; Gelber, Cohava  
 PATENT ASSIGNEE(S): Immulogic Pharmaceutical Corp., USA  
 SOURCE: PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526980	A2	19951012	WO 1995-US4121	19950330
WO 9526980	A3	19951207		
W: AU, CA, JP, KR, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186873	AA	19951012	CA 1995-2186873	19950330
AU 9522383	A1	19951023	AU 1995-22383	19950330
PRIORITY APPLN. INFO.:			US 1994-222206	19940401
			US 1995-383645	19950206
			WO 1995-US4121	19950330
OTHER SOURCE(S):		MARPAT 124:146864		
GI				



AB Class I or II major histocompatibility complex (MHC) antigens-binding carrier peptides linked to catechol derivs. [I; R = H, C1-20 hydrocarbyl; A = peptide of 7-30 amino acid residues capable of binding to a Class II MHC mol.; n = 1,2,3], which are recognized by urushiol-specific T lymphocytes, are prepd. The compds. are useful in therapeutic compns. for desensitizing individuals against contact sensitivity to haptens, such as urushiol of poison ivy/poison oak. Thus, Ac-Phe-Glu-Asp-Gln-Gly-Ser-Lys(R)-Glu-Asn-Ile-Ala-Arg-Asp-NH<sub>2</sub> [I; R = 3-n-pentadecylcatechol (Q), which is a major component of poison ivy urushiol], was prepd. by the solid phase synthesis of the peptide I (R = H) and coupling of the peptide with 3-n-pentadecylbenzoquinone (II) obtained by oxidn. of 3-n-pentadecylcatechol with Ag<sub>2</sub>O. Treatment of mice with the above 3-n-pentadecylcatechol-conjugated peptide reduced the delayed-type hypersensitivity response to down to background level, indicating that pretreatment with this peptide results in downregulation of the effector T cells mediating the delayed-type hypersensitivity response.

IT 173525-55-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of catechol-haptenated peptides for desensitizing against delayed-type hypersensitivity induced by urushiol)

RN 173525-55-8 HCAPLUS


CN L-Threonine, L-prolyl-N6-(3,4-dihydroxy-5-pentadecylphenyl)-L-lysyl-L-tyrosyl-L-valyl-L-lysyl-L-glutaminy-L-asparaginy-L-threonyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



PAGE 2-B

NH2

=>



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN


Full Text Citing References

ACCESSION NUMBER: 2002:946095 HCAPLUS  
 DOCUMENT NUMBER: 138:24322  
 TITLE: Preparation of malonamides as cathepsin inhibitors  
 INVENTOR(S): Patterson, John W.; Zipfel, Sheila  
 PATENT ASSIGNEE(S): Celera, USA  
 SOURCE: PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098406	A1	20021212	WO 2002-US17922	20020604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1399146	A1	20040324	EP 2002-739721	20020604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-295744P P 20010604  
 WO 2002-US17922 W 20020604

OTHER SOURCE(S): MARPAT 138:24322  
 GI



AB The title malonamides I [wherein X1 = substituted amino; R3 = (un)substituted alkyl; R4 = (un)substituted amino; with provisos; and the N-oxide derivs., prodrugs, protected derivs., isomers, mixts. of isomers, pharmaceutically acceptable salts, and solvates thereof] were prepd. as selective cathepsin S inhibitors. For example, a soln. of aniline in

CH<sub>2</sub>Cl<sub>2</sub> was treated with Me malonyl chloride in the presence of Et<sub>3</sub>N, followed by reaction with 1-iodobutane in N-methylpyrrolidinone in the presence of LiOH to give Me 2-phenylcarbamoylhexanoate. The above compd. was treated with NaOH in MeOH, followed by the addn. of 1 N aq. HCl soln. to afford 2-phenylcarbamoylhexanoic acid (74%). The hexanoic acid in DMF was treated with PyBOP, aminoacetonitrile bisulfate, and Et<sub>3</sub>N to provide 2-butyl-N-cyanomethyl-N'-phenylmalonamide (II) (57%). I showed inhibition consts. against cathepsin S in the range of 10<sup>-10</sup> M to 10<sup>-7</sup> M. Pharmaceutical formulations contg. a compd. of formula I were also presented.


IT **477860-85-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(cathepsin inhibitor; prepn. of malonamides via condensation reactions of malonic acids with amines as cathepsin inhibitors)

RN **477860-85-8** HCAPLUS

CN Propanediamide, N-(cyanomethyl)-2-(cyclohexylmethyl)-N'-(4-phenoxyphenyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER:

2002:907188 HCAPLUS

DOCUMENT NUMBER:

138:1673

TITLE:

Inhibitors of histone deacetylase and their therapeutic use

INVENTOR(S):

Curtin, Michael L.; Dai, Yujia; Davidsen, Steven K.; Frey, Robin R.; Guo, Yan; Heyman, Howard R.; Holms, James H.; Ji, Zhiqin; Michaelides, Michael R.; Vasudevan, Anil; Wada, Carol K.

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl. Publ., 49 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002177594	A1	20021128	US 2001-45747	20011026
US 2003045477	A1	20030306	US 2002-205924	20020726
PRIORITY APPLN. INFO.:			US 2001-275770P	P 20010314
			US 2001-308435P	P 20010726

OTHER SOURCE(S): MARPAT 138:1673

AB Compds. having the formula (R<sub>4</sub>L<sub>2</sub>)nL<sub>1</sub>CR<sub>1</sub>R<sub>2</sub>R<sub>3</sub> (n = 1,2; L<sub>1</sub> = alkenylene, alkylene, alkynylene, cycloalkylene, heteroalkylene, alkylene-CONR<sub>5</sub>-alkylene, alkylene-O-alkylene; L<sub>2</sub> = bond, C<sub>2</sub>-alkenylene, O, S, SO<sub>2</sub>,